Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clover Health Investments's enterprise value is $2,067 Mil.
Clover Health Investments's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-55 Mil. Therefore, Clover Health Investments's EV-to-EBITDA for today is -37.44.
The historical rank and industry rank for Clover Health Investments's EV-to-EBITDA or its related term are showing as below:
CLOV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.26 Med: -5.47 Max: 0.65
Current: -37.44
During the past 7 years, the highest EV-to-EBITDA of Clover Health Investments was 0.65. The lowest was -82.26. And the median was -5.47.
CLOV's EV-to-EBITDA is ranked worse than 100% of 15
companies
in the Healthcare Plans industry
Industry Median: 13.5
vs CLOV: -37.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Clover Health Investments (NAS:CLOV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clover Health Investments's PE Ratio (TTM) for today is calculated as:
Clover Health Investments's share price for today is $4.54.
Clover Health Investments's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Healthcare Plans subindustry, Clover Health Investments's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clover Health Investments EV-to-EBITDA vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Clover Health Investments's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clover Health Investments's EV-to-EBITDA falls into.
Clover Health Investments's current Enterprise Value is $2,067 Mil.
Clover Health Investments's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clover Health Investments (CLOV) has a EV-to-EBITDA of -37.44 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clover Health Investments. According to the industry distribution chart, Clover Health Investments ranks #999999 out of 15 companies in the Healthcare Plans industry.
Is Clover Health Investments' EV-to-EBITDA too high?
Clover Health Investments' current EV-to-EBITDA is -37.44. Based on the distribution chart, Clover Health Investments ranks #999999 out of 15 companies in the Healthcare Plans industry, which is in the bottom quartile relative to peers. Overall, Clover Health Investments has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clover Health Investments' EV-to-EBITDA compare to PGNY and ALHC?
According to the Healthcare Plans industry distribution chart, Clover Health Investments ranks #999999 out of 15 companies for EV-to-EBITDA. This places Clover Health Investments in the lower half of its industry. The industry median EV-to-EBITDA is 13.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Plans company?
The median EV-to-EBITDA among Healthcare Plans companies is 13.50, based on 15 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clover Health Investments. For the Healthcare Plans industry, the median EV-to-EBITDA is 13.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clover Health Investments's current EV-to-EBITDA is -37.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Health Investments stock overvalued right now?
Based on GuruFocus' analysis, Clover Health Investments (CLOV) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.06, compared to a current price of $4.54 — trading 11.8% above its estimated fair value. The current EV-to-EBITDA is -37.44. Clover Health Investments' overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Clover Health Investments (CLOV), the current EV-to-EBITDA is -37.44 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clover Health Investments (CLOV) Overvalued in 2026?
Based on GuruFocus' analysis, Clover Health Investments stock appears to be overvalued.
The current stock price of $4.54 is trading 11.8% above its estimated GF Value™ of $4.06.
GuruFocus considers Clover Health Investments to be Modestly Overvalued.
Key valuation signals for CLOV:
EV-to-EBITDA: -37.44
GF Value™: $4.06 vs. price of $4.54 (11.8% above fair value)
No single metric tells the full story. See the CLOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
82GF Score
Get the complete analysis for CLOV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLOV has been successfully added to your 
